H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on ALT stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Patrick Trucchio has given his Buy rating due to a combination of factors including Altimmune’s promising developments in their clinical trials and strategic positioning. The company is entering a pivotal period in 2025 with the anticipated Phase 2b results from the IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). If successful, this trial could mark a significant advancement as pemvidutide may become the first treatment to achieve both MASH resolution and fibrosis improvement with additional benefits of weight loss after just 24 weeks.
Altimmune’s management has already prepared for the next steps, with plans to meet the FDA and potentially start a registrational program in early 2026. Additionally, the company is exploring partnerships for its obesity program and planning further trials in alcohol use disorder and alcohol-associated liver disease. With a solid financial position, clear regulatory strategies, and progress in addressing high-need medical conditions, Altimmune is well-positioned for future growth, justifying the Buy rating and a $12 price target for its shares.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $25.00 price target.